<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Growth factor-independent 1B (GFI1B) is a transcription factor essential for the development and differentiation of erythroid and megakaryocytic lineages </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated the GFI1B expression in <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">erythroleukaemia</z:e> and <z:mpath ids='MPATH_340'>megakaryocytic leukaemia</z:mpath>, as well as in patients with other subtypes of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (ALL), <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:mp ids='MP_0005481'>CML</z:mp>), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), severe aplastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> (SAA), <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> with <z:mpath ids='MPATH_173'>myeloid metaplasia</z:mpath> (MMM) and in healthy volunteers </plain></SENT>
<SENT sid="2" pm="."><plain>GFI1B expression was increased at least threefold in patients with <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">erythroleukaemia</z:e> (P &lt; 0.01 compared with controls) and <z:mpath ids='MPATH_340'>megakaryocytic leukaemia</z:mpath> (P &lt; 0.05) as well as in their corresponding leukaemic cell lines HEL, K562, CMK and M-07e </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with undifferentiated or monocytic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, ALL, MMM, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:mp ids='MP_0005481'>CML</z:mp> had no significantly altered GFI1B expression, whereas GFI1B expression was decreased 10-fold in patients with SAA (P &lt; 0.0001 compared with controls) </plain></SENT>
<SENT sid="4" pm="."><plain>Silencing GFI1B by transfection with small interfering <z:chebi fb="40" ids="33697">RNA</z:chebi> (siRNA) markedly reduced the proliferation rate in the leukaemic cell lines HEL, K562 and NB4 (P &lt; 0.01) </plain></SENT>
<SENT sid="5" pm="."><plain>Concomitantly, we observed a two- to threefold increase in the <z:mpath ids='MPATH_3'>apoptosis</z:mpath> rate in these cells after transfection with siRNA towards GFI1B </plain></SENT>
<SENT sid="6" pm="."><plain>Our data indicate that GFI1B plays a major role in <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">AML-M6</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M7 and qualifies as a target for anti-leukaemic strategies in these <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>